Sustained improvement of psoriasis associated with HCV after virologic response to sofosbuvir/ribavirin

被引:5
|
作者
Elfert, Asem Ahmed [1 ]
机构
[1] Tanta Univ, Fac Med, Dept Trop Med & Infect Dis, Tanta, Egypt
关键词
HCV; Extrahepatic manifestations; Psoriasis; Sofosbuvir; Ribavrin;
D O I
10.1016/j.ajg.2017.09.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
An 18 year old boy attended a dermatology clinic outside our hospital and diagnosed with psoriasis. His skin lesions over both ankles (Fig. 1) did not improve at all with potent local steroids twice for 3 months, then 3 times daily for another 3 months. His dermatologist talked to him about using methotrexate and asked for liver function tests before starting the systemic therapy. His ALT and AST were doubled. The patient came to our Hepatology clinic worried about his elevated liver enzymes. We asked for viral markers. His HCV-Ab was positive, and PCR for HCV-RNA was 650,000 IU/ml. Treatment started with sofosbuvir 400 mg PO once daily plus ribavirin 600 mg at the morning and 400 mg at the evening. After 4 weeks, ALT and AST decreased to normal and PCR for HCV-RNA was <5 IU/ml. All other lab tests were unremarkable. The skin lesions improved markedly (Fig. 2). Now, after 6 months of the end of treatment, sustained virologic response was documented and the skin lesions are almost disappeared without any topical or systemic treatment. © 2017 Pan-Arab Association of Gastroenterology
引用
收藏
页码:234 / 234
页数:1
相关论文
共 50 条
  • [1] Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin
    Meissner, Eric G.
    Nelson, Amy
    Marti, Miriam
    Masur, Henry
    Osinusi, Anu
    Kottilil, Shyam
    OPEN FORUM INFECTIOUS DISEASES, 2014, 1 (01):
  • [2] HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin
    Degasperi, Elisabetta
    De Nicola, Stella
    Rumi, Mariagrazia
    D'Ambrosio, Roberta
    JOURNAL OF HEPATOLOGY, 2016, 65 (05) : 1058 - 1059
  • [3] Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin"
    Maasoumy, Benjamin
    Vermehren, Johannes
    Wedemeyer, Heiner
    Sarrazin, Christoph
    JOURNAL OF HEPATOLOGY, 2016, 65 (05) : 1059 - 1060
  • [4] Peginterferon and ribavirin in HCV: Improvement of sustained viral response
    Ferenci, R.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2008, 22 (06) : 1109 - 1122
  • [5] IMPROVEMENT OF CENTRAL FATIGUE IS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR) FOLLOWING SOFOSBUVIR (SOF) CONTAINING REGIMENS
    Younossi, Z. M.
    Stepanova, M.
    Gerber, L.
    Nader, F.
    Frost, S.
    Hunt, S. L.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S308 - S308
  • [6] Erythropoietin maintains ribavirin dose and sustained virologic response during HCV treatment.
    Senkbeil, LE
    Moss, JG
    Gaglio, PJ
    Dove, LM
    Lobritto, SJ
    Jacobson, IM
    Brown, RS
    HEPATOLOGY, 2003, 38 (04) : 744A - 744A
  • [7] Ribavirin posology, observance, and sustained virologic response
    Couzigou, P.
    Foucher, J.
    Castera, L.
    De Led, V.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (03) : 367 - 367
  • [8] Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antivirals
    Garcia-Fraile, Lucio J.
    Garcia-Buey, Luisa
    Alonso Cerezo, Concepcion
    Sanz Sanz, Jesus
    de los Santos Gil, Ignacio
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2022, 45 (04): : 249 - 255
  • [9] SUSTAINED VIROLOGIC RESPONSE TO DACLATASVIR AND SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN, AMONG PATIENTS IN THE FRENCH DACLATASVIR ATU PROGRAMME INFECTED WITH HCV GENOTYPES 4, 5 AND 6
    Hezode, C.
    Abergel, A.
    Chas, J.
    Conti, F.
    Cotte, L.
    Tateo, M.
    Alric, L.
    Vergniol, J.
    Tomei, C.
    Bernard, P. -H.
    Loustaud-Ratti, V.
    Arpurt, J. -P.
    Blaison, D.
    Larrey, D.
    Fedchuk, L.
    Bennai, Y.
    Filipovics, A.
    Fontaine, F.
    Pageaux, G. -P.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S755 - S755
  • [10] Sofosbuvir and ribavirin for the treatment chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety
    Mccaughan, G.
    Afdhal, N.
    Everson, G.
    Calleja, J. L.
    Symonds, W. T.
    Denning, J.
    Mcnair, L.
    Mchutchison, J. G.
    Arterburn, S.
    Charlton, M.
    Reddy, R.
    Asselah, T.
    Gane, E.
    Forns, X.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 79 - 79